Anzeige
Mehr »
Login
Dienstag, 20.04.2021 Börsentäglich über 12.000 News von 660 internationalen Medien
East Africa Metals: Endlich! Ist das der Startschuss?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1XA8R ISIN: DK0060534915 Ticker-Symbol: NOVC 
Tradegate
20.04.21
16:07 Uhr
60,90 Euro
+0,42
+0,69 %
1-Jahres-Chart
NOVO NORDISK A/S Chart 1 Jahr
5-Tage-Chart
NOVO NORDISK A/S 5-Tage-Chart
RealtimeGeldBriefZeit
60,7260,7716:15
60,7760,7916:15
GlobeNewswire (Europe)
1.373 Leser
Artikel bewerten:
(2)

Novo Nordisk A/S: Novo Nordisk files for regulatory approval in the US of once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes

Bagsværd, Denmark, 20 January 2021 - Novo Nordisk today announced the submission of a label expansion application to the US Food and Drug Administration (FDA) for the existing marketing authorisation for Ozempic, a once-weekly glucagon-like peptide-1 (GLP-1) analogue, to introduce a new dose of 2.0 mg. Ozempic is currently approved in the US in 0.5 mg and 1.0 mg doses for the treatment of type 2 diabetes in adults and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease. The submission follows the application on 29 December 2020 for label extension to the European Medicines Agency (EMA).

The submission is based on the results from the SUSTAIN FORTE trial, which included 961 people with type 2 diabetes in need of treatment intensification. In the trial, people treated with semaglutide 2.0 mg achieved a statistically significant and superior reduction in HbA1c compared to semaglutide 1.0 mg. In the trial, both doses of semaglutide appeared to have safe and well-tolerated profiles. The most common adverse events were gastrointestinal, the vast majority were mild to moderate and diminished over time and were consistent with the GLP-1 receptor agonist class. Compared to semaglutide 1.0 mg, the gastrointestinal adverse events were similar for semaglutide 2.0 mg.

"We are excited about the regulatory submission of semaglutide 2.0 mg to the FDA," said Mads Krogsgaard Thomsen, executive vice president and chief scientific officer of Novo Nordisk. "In the SUSTAIN programme most people achieved the treatment target of HbA1c levels below 7%. However, some patients need treatment intensification and with the 2.0 mg dose, more people with type 2 diabetes will be able to achieve treatment target".

About the SUSTAIN clinical programme
The SUSTAIN clinical development programme for once-weekly subcutaneous semaglutide injection currently comprises 11 phase 3 global clinical trials, including a cardiovascular outcomes trial, involving more than 11,000 adults with type 2 diabetes.

For more information about the SUSTAIN FORTE trial, please read the headline results here

About Novo Nordisk
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 44,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.

Further information

Media:
Anne Margrethe Hauge+45 4442 3450amhg@novonordisk.com (mailto:amhg@novonordisk.com)
Michael Bachner (US)+1 609 664 7308mzyb@novonordisk.com (mailto:mzyb@novonordisk.com)
Investors:
Daniel Muusmann Bohsen+45 3075 2175dabo@novonordisk.com (mailto:dabo@novonordisk.com)
Valdemar Borum Svarrer+45 3079 0301jvls@novonordisk.com (mailto:jvls@novonordisk.com)
Ann Søndermølle Rendbæk+45 3075 2253arnd@novonordisk.com (mailto:arnd@novonordisk.com)
Mark Joseph Root+45 3079 4211mjhr@novonordisk.com (mailto:mjhr@novonordisk.com)
Kristoffer Due Berg (US)+1 609 235 2989krdb@novonordisk.com (mailto:krdb@novonordisk.com)

Company announcement No 3 / 2021

Attachment

  • PR210120_SUSTAIN_Forte_FDA submission (https://ml-eu.globenewswire.com/Resource/Download/9a29821c-a82f-4ef4-b838-3e4b7c794243)

NOVO NORDISK-Aktie komplett kostenlos handeln - auf Smartbroker.de
© 2021 GlobeNewswire (Europe)
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.